By 2024 experts predict that five out of the top ten best-selling drugs will require refrigerated storage and handling. Between 2018 and 2024 there is a projected 50% growth in global biopharma sales for cold chain products, growing at approximately twice the rate of non-cold chain products.
At last week’s HDA Distribution Management Conference, Ann Pham, Director of Business Development at third party logistics provider ICS, discussed cold chain considerations from a 3PL’s point of view. She said that COVID-19 caused significant disruption to pharmaceutical supply channels, but the pandemic alerted the entire industry to become better prepared in the event of a future incident. “At the 3PL level refining and renewing previously developed supply chain, risk management, and business continuity planning strategies became a focus, as well as storing product across multiple locations to decrease the risk event,” said Pham.


















